pIPELINE

RARE DISORDERS AND INFECTIOnS DISEAsES

Pharmaceutical Product Pipeline

 ​Revive is building a pharmaceutical product portfolio targeting rare disorders and infectious diseases.

PHARMACEUTICAL STRATEGY

Clinical development of Psilocybin, Cannabidiol and Bucillamine

targeting rare disorders and infectious disears

novel Uses, formulations and delivery system

targeting FDA designations: Orphan, Fast track, breakthrough therapy and rare pediatric diseases

FORMULATION & DELIVERY TECHNOLOGY

  • Delivering naturally extracted and synthetic psilocybin and cannabinoids
  • PSILOCYBIN – Prescise dosed formulations i.e. capsules, sublingual spray, gel caps, effervescent tablets and oral/transmucosal strips
    • Releases (rapid, controlled, sustained), improved bioavailability, no first-pass etabolism
  • CANNABIDIOL – Novel combination of composites allowing for multiple delivery formats, potential synergistic and therapeutic effects
    • Tannin (plant-based) – antibacterial, antifungal, antioxidant and wound healing
    • Chistosan (shrimp-based) – blood-clotting and antimicrobial properties

PRODUCT PIPELINE

Focus on Infectious Diseases, including COVID-19, AND Rare disorders

Product

Bucillamine

Indication

Infectious Diseases
(Covid-19)

Stage of Development

Filling IND

Regulatory Status

Received FDA
Orphan Status

Market

TBD

Product

CBD

Indication

Liver Diseases
(Autoimmune Hepatitis)

Stage of Development

Filling IND

Regulatory Status

Received FDA
Orphan Status

Market

+ $100M
50k US Pop

Product

Psilocybin

Indication

Undisclosed

Stage of Development

Pre-Clinical

Regulatory Status

Target FDA
Orphan Status

Market

+ $500M

Product

Psilocybin

Indication

Undisclosed Mulitple Indications

Stage of Development

Pre-Clinical

Regulatory Status

Target FDA
Orphan Status

Market

TBD

Bucillamine

Infectious Diseases
(COVID-19)

Received FDA
Orphan Satus

TBD

Bucillamine

Liver Diseases
(Autoimmune Hepatitis)

Filing IND

Received FDA
Orphan Satus

+ $100M
50K US Pop

Psilocybin

Undislocsed

Pre-Clinical 

Target FDA
Orphan Status

+ $500M

Psilocybin

Undislocsed Multiple Indications

Pre-Clinical 

Target FDA
Orphan Status

TBD

As for its rare disease pharmaceutical product pipeline, Revive has been granted by the U.S. Food and Drug Administration (“FDA”) two orphan drug designations for cannabidiol (“CBD”) in the treatment of autoimmune hepatitis, a rare liver disease, and CBD in the prevention of ischemia and reperfusion injury (“IRI”) resulting from solid organ transplantation, such as liver, kidney, heart and lung.

​Revive aims to build a portfolio of FDA orphan drug designations of cannabinoids that are complementary to Revive’s cannabis-based pharmaceuticals initiatives that support the long-term potential of cannabinoid prescription medicines for rare diseases and disorders, which the Company believes has been validated by the FDA approval of the GW Pharmaceuticals plc EPIDIOLEX®.